Back to the future: Antibody-based strategies for the treatment of infectious diseases


Oral H. B. , Ozakin C., Akdis C.

Applied Biochemistry and Biotechnology - Part B Molecular Biotechnology, vol.21, no.3, pp.225-239, 2002 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 21 Issue: 3
  • Publication Date: 2002
  • Doi Number: 10.1385/mb:21:3:225
  • Journal Name: Applied Biochemistry and Biotechnology - Part B Molecular Biotechnology
  • Journal Indexes: Science Citation Index Expanded, Scopus
  • Page Numbers: pp.225-239
  • Keywords: antibody therapy, infectious diseases, immunoglobulin, HUMAN-IMMUNODEFICIENCY-VIRUS, TUMOR-NECROSIS-FACTOR, HUMAN MONOCLONAL-ANTIBODY, PLACEBO-CONTROLLED TRIAL, INTRAVENOUS IMMUNOGLOBULIN THERAPY, BONE-MARROW TRANSPLANTATION, GRAM-NEGATIVE BACTEREMIA, B IMMUNE GLOBULIN, LIPID-A DOMAIN, SEPTIC SHOCK

Abstract

Before antibiotics, sera from immune animals and humans were used to treat a variety of infectious diseases, often with successful results. After the discovery of antimicrobial agents, serum therapy for bacterial infections was rapidly forsaken. In the last two decades, problems with treatment of newly emerged, reemerged, or persistent infectious diseases necessitated researchers to develop new and/or improved antibody-based therapeutic approaches. This article reviews some information on the use of antibodies for the treatment of infectious diseases, with special reference to the most seminal discoveries and current advances as well as available treatment approaches in this field.